Clarifying the vision.

The VISION trial showed that Lu-177-PSMA-617 improved survival when added to standard treatment of men with PSMA-positive metastatic castrate-resistant prostate cancer that progresses after androgen receptor pathway inhibitor and taxane chemotherapy. But there’s a lot left to clarify. This detailed review covers all things PSMA-therapy including ideal patient selection, individualized prognostication, and future directions for improving efficacy either by using an α-emitters or combining with other systemic agents such as immune checkpoint inhibitors, PARP-inhibitors, antiandrogens, etc. | Gafita, Am Soc Clin Oncol Educ Book 2022


Popular Posts